Skip to content

Study · Not a test of the peptide alone · 2009

6 results

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ

International journal of clinical pharmacology and therapeutics1 Aug 2009Cited by 19 (Europe PMC)

PMID19640359 (opens in a new tab)DOI10.5414/cpp47501 (opens in a new tab)PepBankPUB-19640359
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, exenatide and insulin glargine produced comparable projected life expectancy.

    In plain wordsIn a computer model of diabetes, exenatide and insulin glargine produced similar projected life expectancy.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedProjected life expectancy
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Mortality · Whole body

    Source sentences

    Summary
    In the base-case analysis exenatide was associated with comparable life expectancy (11,549 years versus 11,468 years) and an improvement in quality-adjusted life expectancy of 0.43 quality-adjusted life years (QALYs) versus insulin glargine over a 35-year time horizon.
    2 context sentences
    Summary · context
    To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting.
    Summary · context
    A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life expectancy and direct medical costs over a 35-year time horizon.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, exenatide increased projected quality-adjusted life expectancy versus insulin glargine.

    In plain wordsIn a computer model of diabetes, exenatide increased projected quality-adjusted life expectancy compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseProjected quality-adjusted life expectancy
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Quality of life · Whole body

    Measurements

    Quality-adjusted life expectancy difference
    0.43 QALYs
    exenatide versus insulin glargine

    Source sentences

    Summary
    In the base-case analysis exenatide was associated with comparable life expectancy (11,549 years versus 11,468 years) and an improvement in quality-adjusted life expectancy of 0.43 quality-adjusted life years (QALYs) versus insulin glargine over a 35-year time horizon.
    2 context sentences
    Summary · context
    To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting.
    Summary · context
    A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life expectancy and direct medical costs over a 35-year time horizon.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, exenatide reduced projected cumulative incidence of most diabetes complications versus insulin glargine.

    In plain wordsIn a computer model of diabetes, exenatide reduced projected diabetes complications compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProjected diabetes complications
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Diabetes complications · Whole body

    Source sentences

    Summary
    Exenatide was associated with a reduced cumulative incidence of most diabetes-related complications including an absolute reduction in myocardial infarction by 0.28%.
    2 context sentences
    Summary · context
    To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting.
    Summary · context
    A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life expectancy and direct medical costs over a 35-year time horizon.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a diabetes simulation, exenatide reduced projected myocardial infarction incidence versus insulin glargine.

    In plain wordsIn a computer model of diabetes, exenatide reduced projected heart attack incidence compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseProjected myocardial infarction
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Absolute myocardial infarction reduction
    0.28%
    exenatide versus insulin glargine

    Source sentences

    Summary
    Exenatide was associated with a reduced cumulative incidence of most diabetes-related complications including an absolute reduction in myocardial infarction by 0.28%.
    2 context sentences
    Summary · context
    To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting.
    Summary · context
    A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life expectancy and direct medical costs over a 35-year time horizon.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 05Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a Swiss diabetes simulation, exenatide increased projected direct costs versus insulin glargine over the modeled horizon.

    In plain wordsIn a Swiss computer model of diabetes, exenatide increased projected direct costs compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseProjected direct medical costs
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Measurements

    Direct cost increase
    8378 CHF per patient
    35-year horizon

    Source sentences

    Summary
    Assuming an annual treatment cost of CHF 2,797.74 for exenatide, direct costs increased by CHF 8,378 per patient over the 35-year time horizon compared to insulin glargine.
    2 context sentences
    Summary · context
    To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting.
    Summary · context
    A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life expectancy and direct medical costs over a 35-year time horizon.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 06Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther

    In a Swiss diabetes simulation, exenatide had the reported incremental cost per quality-adjusted life year gained versus insulin glargine.

    In plain wordsIn a Swiss computer model of diabetes, exenatide had the reported extra cost per quality-adjusted life year compared with insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableIncremental cost-effectiveness ratio
    Study

    n: not reported in source

    Computer simulation model of diabetes
    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body

    Measurements

    Incremental cost-effectiveness ratio
    19,450 CHF per QALY
    exenatide versus insulin glargine

    Source sentences

    Summary
    The resultant incremental cost-effectiveness ratio was CHF 19,450 per QALY gained for exenatide versus insulin glargine.
    2 context sentences
    Summary · context
    To investigate the long-term clinical and economic outcomes associated with exenatide versus insulin glargine as "add-on" treatments to oral therapy in individuals with Type 2 diabetes inadequately controlled with combination oral agents in the Swiss setting.
    Summary · context
    A computer simulation model of diabetes was used to project complications, life expectancy, quality-adjusted life expectancy and direct medical costs over a 35-year time horizon.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.